Not Applicable
Not Applicable
1. Field of the Invention
In some embodiments this invention relates to implantable medical devices, their manufacture, and methods of use. Some embodiments are directed to delivery systems, such as catheter systems of all types, which are utilized in the delivery of such devices.
2. Description of the Related Art
A stent is a medical device introduced to a body lumen and is well known in the art. Typically, a stent is implanted in a blood vessel at the site of a stenosis or aneurysm endoluminally, i.e. by so-called “minimally invasive techniques” in which the stent in a radially reduced configuration, optionally restrained in a radially compressed configuration by a sheath and/or catheter, is delivered by a stent delivery system or “introducer” to the site where it is required. The introducer may enter the body from an access location outside the body, such as through the patient's skin, or by a “cut down” technique in which the entry blood vessel is exposed by minor surgical means.
Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices, collectively referred to hereinafter as stents, are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. Stents may be used to reinforce body vessels and to prevent restenosis following angioplasty in the vascular system. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).
Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.
Within the vasculature it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) may affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels.
Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.
There remains a need for innovative bifurcated stents which may be deployed using a single balloon for the main section and an alternate mechanism for the side branch support. There also remains a need for bifurcated stents with innovative designs in the region of the bifurcation to provide adequate coverage of the carina. The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.
All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.
Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.
A brief abstract of the technical disclosure in the specification is provided as well only for the purposes of complying with 37 C.F.R. 1.72. The abstract is not intended to be used for interpreting the scope of the claims.
In at least one embodiment, the invention is directed to a stent comprising a proximal stent and a distal stent. Each stent has a tubular body defining a stent lumen, a longitudinal axis and a circumference. A proximal flap extends from the distal end of the proximal stent and a distal flap extends from the proximal end of the distal stent.
In at least one embodiment, each flap is characterized as a non-tubular or substantially planar structure which defines only a portion of the circumference of the otherwise tubular body of a given stent.
In at least one embodiment, the flaps comprise a cross-sectional length equal to about half the circumference of the tubular body. In some embodiments the cross-sectional length is greater or less than about half the circumference of the tubular body.
The stents are expandable from a reduced diameter configuration in an unexpanded or pre-deployed state to a greater diameter in an expanded or deployed state. When the stents are properly positioned at a bifurcation junction of two vessels and are expanded to their expanded states, the proximal flap and the distal flap will extend into the secondary or side branch vessel of the bifurcation to effectively form a side branch support structure by way of their adjacency to one another. This side branch support will define a side branch support lumen which is in fluid communication with the common lumen(s) defined by the tubular bodies of the adjacent stents.
The “expanded state” of the flaps, refers to the positional state of the flaps wherein the flaps each extend obliquely from the tubular body of the stent segment and form the side branch support which, in at least one embodiment, covers the contra-lateral wall and carina, of the ostium region, of the secondary vessel, of the bifurcation.
In at least one embodiment, the tubular bodies are positioned with the ends which include the flaps immediately adjacent one another.
In at least one embodiment, in the expanded state the tubular bodies are engaged to one another.
In at least one embodiment, the proximal stent and the distal stent are welded to one another.
In at least one embodiment, the flaps of the proximal stent segment and the distal stent segment overlap one another.
In at least one embodiment, the flaps of the proximal stent segment and the distal stent segment nest within each other.
In at least one embodiment, the stent assembly is constructed at least partially from a self-expanding material.
In at least one embodiment, the stent assembly is balloon expandable.
In at least one embodiment, the flaps are constructed of self-expanding material. In at least one embodiment, the flaps self-expand to form the side branch support lumen.
In at least one embodiment, at least a portion of the stent assembly is constructed and arranged to carry a therapeutic agent. In at least one embodiment, the therapeutic agent is a coating on the stent assembly. In at least one embodiment, at least one of the flaps contains a different dosing of therapeutic agent than the tubular body from which it extends.
In at least one embodiment, the side branch support lumen is substantially oval-shaped.
In at least one embodiment, the side branch support lumen is substantially polygonal.
In at least one embodiment, the invention is directed to a delivery system for delivering a stent assembly to a vessel bifurcation comprising a catheter and a proximal stent and a distal stent mounted thereon. The stents comprise an assembly wherein, in the unexpanded state the stent assembly can be disposed about the stent retaining region of the catheter shaft. The stent assembly has a tubular body which defines a primary lumen therethrough. In at least one embodiment, flaps extend from both the proximal stent and the distal stent. Each flap comprises a non-tubular body having a substantially planar structure. In at least one embodiment, in the expanded state the flaps form a side branch support having a side branch support lumen which is in fluid communication with the primary lumen.
In at least one embodiment, the delivery system also has a side branch support guide housing. The support guide housing has a tubular member which defines a secondary guidewire lumen therethrough. In at least one embodiment, the side branch support guide housing can be positioned adjacent to the stent retaining region of the catheter shaft. In at least one embodiment, a first portion of the guide housing can extend within the primary lumen defined by the proximal stent and exit the primary lumen through the side branch support lumen.
In at least one embodiment, in the unexpanded state one flap overlays the other.
In at least one embodiment, in the expanded state the proximal flap and the distal flap do not contact one another.
In at least one embodiment, the stent assembly can be assembled by providing a proximal stent having a flap and a distal stent having a flap and moving the proximal stent and the distal stent together such that the flaps form a side branch support.
In at least one embodiment, the proximal stent and the distal stent can be moved together while both are disposed about a catheter.
In at least one embodiment, a method of delivering a stent to a bifurcation comprises the steps of a) advancing any of the stent assemblies above disposed about a catheter along two guidewires and b) deploying the stent at the bifurcation site.
In at least one embodiment, a method of delivering a stent to a bifurcation comprises the steps of a) advancing any of the stent assemblies above disposed about a catheter along two guidewires, the catheter having a catheter shaft and catheter balloon, the stent assembly disposed about the catheter balloon and b) deploying the stent assembly at the bifurcation site by expanding the catheter balloon. In at least one embodiment, expansion of the catheter balloon acts on the stent assembly to expand the stent assembly such that the stent assembly expands to an expanded state.
These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for further understanding of the invention, its advantages and objectives obtained by its use, reference should be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described an embodiments of the invention.
A detailed description of the invention is hereafter described with specific reference being made to the drawings.
While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.
For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.
In
The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.
In
In some embodiments the dimensions of the flaps 40 and 50 are the same, while in others they are different. For example, the proximal flap may be longer than the distal flap or vice versa. In some embodiments the arcuate length (width) and/or longitudinal length of one flap may be greater than the other flap. In some embodiment the distal flap 40 is larger than the proximal flap 50. The distal flap 40 in some embodiments is longer than the distal stent 30. In the expanded state the distal end 45 of proximal stent 20 and the proximal end 55 of distal stent 30 are adjacent one another. In some embodiments, the stent segments are in contact with one another. In some embodiments there is a gap between the distal end 45 and the proximal end 55 in the expanded state. In an expanded state the proximal stent lumen and the distal stent lumen form stent lumen 35.
As illustrated in
As depicted in
In some embodiments the at least a portion of the stent is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto. The therapeutic agent can be applied in a variety of ways and can include therapeutic agent being applied in some locations more than others. In at least one embodiment as shown in
A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.
The stent assembly may be assembled on or off a catheter.
In some embodiments, the guidewires 116 and 118 are inserted into the body to the bifurcation site before the catheter 110 and stent assembly 10 are mounted on the guidewires. The primary guidewire 116 is advanced through the primary vessel lumen 130 to beyond the bifurcation site, and the secondary guidewire 118 is advanced through the primary vessel lumen 130 and at the bifurcation site is advanced into secondary vessel lumen 120. In at least one embodiment, once the primary guidewire 116 is in place within the primary vessel lumen 130 and the secondary guidewire is positioned to extend into the secondary vessel lumen 120 such as in the manner shown in
In the embodiment shown in
Once the system is aligned in the manner shown in
In some embodiments the stent retaining region 114 comprises a balloon 114′. By expanding the balloon 114′ from a reduced diameter to a greater, expanded diameter the balloon 114′ will exert expansion and/or deployment forces upon the assembly 10. The expansion forces exerted on the assembly are sufficient to expand the assembly to its deployed state within the vessel bifurcation. Subsequent to the expansion of the assembly 10, the catheter is removed from the vessel lumens 120 and 130, and the assembly 10 remains in place to support the bifurcation. In some embodiments additional radial force within the side branch support lumen may be used to expand side branch support 90.
The stent assembly 10 may also have self-expanding portions. In some embodiments the entire stent assembly 10 is made of self-expanding material; in some embodiments the entire stent assembly 10 is made of non-self-expanding material. In some embodiments, the tubular body portions are made of non-self-expanding material and the side branch support is made of self-expanding material. In some embodiments, the tubular body portions are made of self-expanding material and the side branch support is made of non-self-expanding material.
The stent assembly 10 may be assembled off the catheter. The proximal stent 20 and the distal stent 30 may be assembled such that the distal end 45 of proximal stent 20 and the proximal end 55 of distal stent 30 are adjacent one another as illustrated in
In some embodiments the stent assembly 10 has only one flap 40 between the proximal stent 20 and the distal stent 30 as shown in
In the expanded state the flap 40 of the stent assembly 10 illustrated in
In at least one embodiment an example of which is shown in
The stent assembly 10 is shown expanded in
The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy and nickel-titanium alloys, for example, Nitinol.
The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon being heated to a transition temperature and having any restraints removed therefrom.
In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.
Further, the particular features presented in the dependent claims may be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.
This completes the description of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.
Number | Name | Date | Kind |
---|---|---|---|
4309994 | Grunwald | Jan 1982 | A |
4769005 | Ginsburg et al. | Sep 1988 | A |
4774949 | Fogarty | Oct 1988 | A |
4896670 | Crittenden | Jan 1990 | A |
4905667 | Foerster et al. | Mar 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5342387 | Summers | Aug 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5476471 | Shifrin et al. | Dec 1995 | A |
5487730 | Marcadis et al. | Jan 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5609605 | Marshall et al. | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5669932 | Fischell et al. | Sep 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683450 | Goicoechea et al. | Nov 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5707348 | Krogh | Jan 1998 | A |
5709713 | Evans et al. | Jan 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755734 | Richter et al. | May 1998 | A |
5755735 | Richter et al. | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5827320 | Richter et al. | Oct 1998 | A |
5851464 | Davila et al. | Dec 1998 | A |
5868777 | Lam | Feb 1999 | A |
5893887 | Jayaraman | Apr 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5961548 | Shmulewitz | Oct 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
6013054 | Yan | Jan 2000 | A |
6013091 | Ley et al. | Jan 2000 | A |
6017324 | Tu et al. | Jan 2000 | A |
6017363 | Hojeibane | Jan 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6056775 | Borghi et al. | May 2000 | A |
6059824 | Taheri | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6086611 | Duffy et al. | Jul 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099497 | Adams et al. | Aug 2000 | A |
6113579 | Eidenschink et al. | Sep 2000 | A |
6117117 | Mauch | Sep 2000 | A |
6117156 | Richter et al. | Sep 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6142973 | Carleton et al. | Nov 2000 | A |
6143002 | Vietmeier | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6168621 | Vrba | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6210380 | Mauch | Apr 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6210433 | Larre | Apr 2001 | B1 |
6254593 | Wilson | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264662 | Lauterjung | Jul 2001 | B1 |
6264682 | Wilson et al. | Jul 2001 | B1 |
6264686 | Rieu et al. | Jul 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6293968 | Taheri | Sep 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6346089 | Dibie | Feb 2002 | B1 |
6355060 | Lenker et al. | Mar 2002 | B1 |
6361544 | Wilson et al. | Mar 2002 | B1 |
6361555 | Wilson | Mar 2002 | B1 |
6383213 | Wilson et al. | May 2002 | B2 |
6395018 | Castaneda | May 2002 | B1 |
6436104 | Hojeibane | Aug 2002 | B2 |
6436134 | Richter et al. | Aug 2002 | B2 |
6508836 | Wilson et al. | Jan 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6540779 | Richter et al. | Apr 2003 | B2 |
6579309 | Loos et al. | Jun 2003 | B1 |
6579312 | Wilson et al. | Jun 2003 | B2 |
6582394 | Reiss et al. | Jun 2003 | B1 |
6596020 | Vardi et al. | Jul 2003 | B2 |
6599316 | Vardi et al. | Jul 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6689156 | Davidson et al. | Feb 2004 | B1 |
6692483 | Vardi et al. | Feb 2004 | B2 |
6695877 | Brucker et al. | Feb 2004 | B2 |
6706062 | Vardi et al. | Mar 2004 | B2 |
6749628 | Callol et al. | Jun 2004 | B1 |
6776793 | Brown et al. | Aug 2004 | B2 |
6811566 | Penn et al. | Nov 2004 | B1 |
6835203 | Vardi et al. | Dec 2004 | B1 |
6858038 | Heuser | Feb 2005 | B2 |
6884258 | Vardi et al. | Apr 2005 | B2 |
6896699 | Wilson et al. | May 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6945995 | Nicholas | Sep 2005 | B2 |
6955687 | Richter et al. | Oct 2005 | B2 |
6955688 | Wilson et al. | Oct 2005 | B2 |
6962602 | Vardi et al. | Nov 2005 | B2 |
7018400 | Lashinski et al. | Mar 2006 | B2 |
7056323 | Mareiro et al. | Jun 2006 | B2 |
7060091 | Killion et al. | Jun 2006 | B2 |
20010003161 | Vardi et al. | Jun 2001 | A1 |
20010004706 | Hojeibane | Jun 2001 | A1 |
20010004707 | Dereurne et al. | Jun 2001 | A1 |
20010012927 | Mauch | Aug 2001 | A1 |
20010016766 | Vardi et al. | Aug 2001 | A1 |
20010016767 | Wilson et al. | Aug 2001 | A1 |
20010016768 | Wilson et al. | Aug 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010027291 | Shanley | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010029396 | Wilson et al. | Oct 2001 | A1 |
20010037116 | Wilson et al. | Nov 2001 | A1 |
20010037138 | Wilson et al. | Nov 2001 | A1 |
20010039448 | Dibie | Nov 2001 | A1 |
20010049548 | Vardi et al. | Dec 2001 | A1 |
20010049552 | Richter et al. | Dec 2001 | A1 |
20010056297 | Hojeibane | Dec 2001 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020013619 | Shanley | Jan 2002 | A1 |
20020022874 | Wilson | Feb 2002 | A1 |
20020026232 | Marotta et al. | Feb 2002 | A1 |
20020035392 | Wilson | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020052648 | McGuckin, Jr. et al. | May 2002 | A1 |
20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
20020111675 | Wilson | Aug 2002 | A1 |
20020151953 | Chobotov et al. | Oct 2002 | A1 |
20020156516 | Vardi et al. | Oct 2002 | A1 |
20020156517 | Perouse | Oct 2002 | A1 |
20020165604 | Shanley | Nov 2002 | A1 |
20020173835 | Bourang et al. | Nov 2002 | A1 |
20020173839 | Leopold et al. | Nov 2002 | A1 |
20020173840 | Brucker et al. | Nov 2002 | A1 |
20020183763 | Callol et al. | Dec 2002 | A1 |
20020193872 | Trout, III et al. | Dec 2002 | A1 |
20020193873 | Brucker et al. | Dec 2002 | A1 |
20030009209 | Hojeibane | Jan 2003 | A1 |
20030028233 | Vardi et al. | Feb 2003 | A1 |
20030045926 | Pinchasik | Mar 2003 | A1 |
20030050688 | Fischell et al. | Mar 2003 | A1 |
20030055378 | Wang et al. | Mar 2003 | A1 |
20030055483 | Gumm | Mar 2003 | A1 |
20030074047 | Richter | Apr 2003 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030097169 | Brucker | May 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030135259 | Simso | Jul 2003 | A1 |
20030181923 | Vardi | Sep 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20030204245 | Brightbill | Oct 2003 | A1 |
20040006381 | Sequin et al. | Jan 2004 | A1 |
20040015227 | Vardi et al. | Jan 2004 | A1 |
20040044396 | Clerc et al. | Mar 2004 | A1 |
20040044398 | Nicholas | Mar 2004 | A1 |
20040059406 | Cully et al. | Mar 2004 | A1 |
20040088007 | Eidenschink | May 2004 | A1 |
20040093067 | Israel | May 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040133268 | Davidson et al. | Jul 2004 | A1 |
20040138732 | Suhr et al. | Jul 2004 | A1 |
20040138737 | Davidson et al. | Jul 2004 | A1 |
20040148006 | Davidson et al. | Jul 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040186560 | Alt | Sep 2004 | A1 |
20040215327 | Doig et al. | Oct 2004 | A1 |
20040225345 | Fischell et al. | Nov 2004 | A1 |
20040267352 | Davidson et al. | Dec 2004 | A1 |
20050004656 | Das | Jan 2005 | A1 |
20050010278 | Vardi et al. | Jan 2005 | A1 |
20050015108 | Williams et al. | Jan 2005 | A1 |
20050015135 | Shanley | Jan 2005 | A1 |
20050021128 | Nakahama et al. | Jan 2005 | A1 |
20050060027 | Khenansho et al. | Mar 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050102021 | Osborne | May 2005 | A1 |
20050102023 | Yadin et al. | May 2005 | A1 |
20050119731 | Brucker et al. | Jun 2005 | A1 |
20050125076 | Ginn | Jun 2005 | A1 |
20050131526 | Wong | Jun 2005 | A1 |
20050149161 | Eidenschink et al. | Jul 2005 | A1 |
20050154442 | Eidenschink et al. | Jul 2005 | A1 |
20050154444 | Quadri | Jul 2005 | A1 |
20050183259 | Eidenschink et al. | Aug 2005 | A1 |
20050209673 | Shaked | Sep 2005 | A1 |
20050228483 | Kaplan et al. | Oct 2005 | A1 |
20060036315 | Yadin et al. | Feb 2006 | A1 |
20060041303 | Israel | Feb 2006 | A1 |
20060079956 | Eigler et al. | Apr 2006 | A1 |
20060173528 | Feld et al. | Aug 2006 | A1 |
20060287712 | Eidenschink | Dec 2006 | A1 |
20070073376 | Krolik et al. | Mar 2007 | A1 |
Number | Date | Country |
---|---|---|
2220864 | Jul 1999 | CA |
9014845 | Feb 1991 | DE |
29701758 | Mar 1997 | DE |
29701883 | May 1997 | DE |
0479730 | Oct 1991 | EP |
0751752 | Jan 1997 | EP |
0783873 | Jul 1997 | EP |
0804907 | Nov 1997 | EP |
0479557 | Jul 1998 | EP |
0876805 | Nov 1998 | EP |
0880949 | Dec 1998 | EP |
0891751 | Jan 1999 | EP |
0895759 | Feb 1999 | EP |
0904745 | Mar 1999 | EP |
0937442 | Aug 1999 | EP |
0347023 | Dec 1999 | EP |
1031328 | Aug 2000 | EP |
1031329 | Aug 2000 | EP |
0883384 | Dec 2000 | EP |
0862392 | Aug 2001 | EP |
0808140 | Dec 2001 | EP |
0884028 | Feb 2002 | EP |
1190685 | Mar 2002 | EP |
0897700 | Jul 2002 | EP |
0684022 | Feb 2004 | EP |
1 470 797 | Oct 2004 | EP |
1157674 | Jul 2005 | EP |
1031330 | Nov 2005 | EP |
1070513 | Jun 2006 | EP |
2678508 | Jan 1993 | FR |
2740346 | Oct 1995 | FR |
2756173 | Nov 1996 | FR |
2337002 | May 1998 | GB |
8806026 | Aug 1988 | WO |
9521592 | Aug 1995 | WO |
9629955 | Oct 1996 | WO |
9634580 | Nov 1996 | WO |
9641592 | Dec 1996 | WO |
9707752 | Mar 1997 | WO |
9715346 | May 1997 | WO |
9716217 | May 1997 | WO |
9726936 | Jul 1997 | WO |
9741803 | Nov 1997 | WO |
9745073 | Dec 1997 | WO |
9746174 | Dec 1997 | WO |
9819628 | May 1998 | WO |
9836709 | Aug 1998 | WO |
9837833 | Sep 1998 | WO |
9847447 | Oct 1998 | WO |
9848879 | Nov 1998 | WO |
9903426 | Jan 1999 | WO |
9904726 | Feb 1999 | WO |
9915103 | Apr 1999 | WO |
9915109 | Apr 1999 | WO |
9924104 | May 1999 | WO |
9934749 | Jul 1999 | WO |
9936002 | Jul 1999 | WO |
9936015 | Jul 1999 | WO |
9944539 | Sep 1999 | WO |
9956661 | Nov 1999 | WO |
9965419 | Dec 1999 | WO |
0007523 | Feb 2000 | WO |
0010489 | Mar 2000 | WO |
0016719 | Mar 2000 | WO |
0027307 | May 2000 | WO |
0027463 | May 2000 | WO |
0028922 | May 2000 | WO |
0145594 | Jun 2000 | WO |
0044307 | Aug 2000 | WO |
0044309 | Aug 2000 | WO |
0047134 | Aug 2000 | WO |
0048531 | Aug 2000 | WO |
0049951 | Aug 2000 | WO |
0051523 | Sep 2000 | WO |
0057813 | Oct 2000 | WO |
0067673 | Nov 2000 | WO |
0071054 | Nov 2000 | WO |
0071055 | Nov 2000 | WO |
0074595 | Dec 2000 | WO |
0121095 | Mar 2001 | WO |
0121109 | Mar 2001 | WO |
0121244 | Mar 2001 | WO |
0135715 | May 2001 | WO |
0135863 | May 2001 | WO |
0139697 | Jun 2001 | WO |
0139699 | Jun 2001 | WO |
0141677 | Jun 2001 | WO |
0143665 | Jun 2001 | WO |
0143809 | Jun 2001 | WO |
0145785 | Jun 2001 | WO |
0149342 | Jul 2001 | WO |
0154621 | Aug 2001 | WO |
0154622 | Aug 2001 | WO |
0158385 | Aug 2001 | WO |
0160284 | Aug 2001 | WO |
0170294 | Sep 2001 | WO |
0170299 | Sep 2001 | WO |
0174273 | Oct 2001 | WO |
0189409 | Nov 2001 | WO |
0200138 | Jan 2002 | WO |
02053066 | Jul 2002 | WO |
02068012 | Sep 2002 | WO |
03007842 | Jan 2003 | WO |
03055414 | Jul 2003 | WO |
03063924 | Aug 2003 | WO |
2004026174 | Apr 2004 | WO |
2004026180 | Apr 2004 | WO |
2005009295 | Feb 2005 | WO |
2005014077 | Feb 2005 | WO |
2006028925 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20070055351 A1 | Mar 2007 | US |